SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...
Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.
This article uses today’s market data to explore the next cryptocurrency to explode. Below are details of what makes these ...
Pharmaceutical Technology on MSN4d
Leveragen and Moonlight Bio unite for T-cell therapy developmentLeveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
The new official White House bio for Trump reads more like a campaign pitch. And it opens with a falsehood, claiming he won a ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, ...
Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback